RAPA-501-Allo / Rapa Therap - LARVOL DELTA

RAPA-501-Allo Therapy of COVID-19-ARDS (clinicaltrials.gov) - P2; N=1; Terminated; Sponsor: Rapa Therapeutics LLC; N=88 ➔ 1; Trial completion date: Jun 2022 ➔ Sep 2021; Recruiting ➔ Terminated; Trial primary completion date: Dec 2021 ➔ Sep 2021; Change in eligible patient population

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • PCR

RAPA-501-Allo Off-the-Shelf Therapy of COVID-19 (clinicaltrials.gov) - P2; N=88; Recruiting; Sponsor: Rapa Therapeutics LLC; Not yet recruiting ➔ Recruiting

Enrollment open • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • PCR

RAPA-501-Allo Off-the-Shelf Therapy of COVID-19 (clinicaltrials.gov) - P2; N=88; Not yet recruiting; Sponsor: Rapa Therapeutics LLC; Trial completion date: Feb 2022 ➔ Jun 2022

Trial completion date • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • PCR

RAPA-501 Therapy for ALS (clinicaltrials.gov) - P1/2; N=18; Not yet recruiting; Sponsor: Rapa Therapeutics LLC; Phase classification: P1 ➔ P1/2

Phase classification • Amyotrophic Lateral Sclerosis • CNS Disorders • Complement-mediated Rare Disorders

Phase update (clinicaltrials.gov) - P1➔P2, ALS

Phase shift • Amyotrophic Lateral Sclerosis

RAPA-501-Allo Off-the-Shelf Therapy of COVID-19 (clinicaltrials.gov) - P2; N=88; Not yet recruiting; Sponsor: Rapa Therapeutics LLC

New P2 trial • Immune Modulation • Infectious Disease • Novel Coronavirus Disease • PCR

RAPA-501 Therapy for ALS (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Rapa Therapeutics LLC

New P1 trial